Multi-visceral resection for left-sided pancreatic ductal adenocarcinoma: a multicenter retrospective analysis from European countries.


Journal

Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285

Informations de publication

Date de publication:
30 Sep 2023
Historique:
received: 12 03 2023
accepted: 14 09 2023
medline: 2 10 2023
pubmed: 1 10 2023
entrez: 30 9 2023
Statut: epublish

Résumé

Due to delayed diagnosis and a lower surgical indication rate, left-sided pancreatic ductal adenocarcinoma (PDAC) is often associated with a poor prognosis in comparison to pancreatic head tumors. Multi-visceral resections (MVR) associated with distal pancreatectomy could be proposed for patients presenting with locally infiltrating disease. We retrospectively analyzed a multi-centric cohort of left-sided PDAC patients operated on from 2009 to 2020. Thirteen European high-volume HPB centers participated in this study. We analyzed patients who underwent distal pancreatectomy (DP) associated with MVR and compared them to standard DP patients. Among 258 patients treated curatively for PDAC of the body and tail, 28 patients successfully underwent MVR. A longer operative time was observed in the MVR group (295 min +/- 74 vs. 250 min +/- 96, p= 0.248). The post-operative complication rate was comparable between the two groups (46.4% in the MVR group vs. 62.2% in the control group, p= 0.108). The incidence of positive margin (R1) was similar between the two groups (28.6% vs. 26.6%; p=0.827). After a median follow-up of 25 (9-111) months, overall survival was comparable between the two groups (p= 0.519). Multi-visceral resection in left-sided pancreatic ductal adenocarcinoma is safe and feasible and should be considered in selected cases as it seems to provide acceptable surgical and oncological outcomes.

Sections du résumé

BACKGROUND BACKGROUND
Due to delayed diagnosis and a lower surgical indication rate, left-sided pancreatic ductal adenocarcinoma (PDAC) is often associated with a poor prognosis in comparison to pancreatic head tumors. Multi-visceral resections (MVR) associated with distal pancreatectomy could be proposed for patients presenting with locally infiltrating disease.
METHODS METHODS
We retrospectively analyzed a multi-centric cohort of left-sided PDAC patients operated on from 2009 to 2020. Thirteen European high-volume HPB centers participated in this study. We analyzed patients who underwent distal pancreatectomy (DP) associated with MVR and compared them to standard DP patients.
RESULTS RESULTS
Among 258 patients treated curatively for PDAC of the body and tail, 28 patients successfully underwent MVR. A longer operative time was observed in the MVR group (295 min +/- 74 vs. 250 min +/- 96, p= 0.248). The post-operative complication rate was comparable between the two groups (46.4% in the MVR group vs. 62.2% in the control group, p= 0.108). The incidence of positive margin (R1) was similar between the two groups (28.6% vs. 26.6%; p=0.827). After a median follow-up of 25 (9-111) months, overall survival was comparable between the two groups (p= 0.519).
CONCLUSIONS CONCLUSIONS
Multi-visceral resection in left-sided pancreatic ductal adenocarcinoma is safe and feasible and should be considered in selected cases as it seems to provide acceptable surgical and oncological outcomes.

Identifiants

pubmed: 37776339
doi: 10.1007/s00423-023-03110-0
pii: 10.1007/s00423-023-03110-0
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

386

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Brennan MF, Moccia RD, Klimstra D (1996) Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg 223(5):506–511 discussion 511-502
doi: 10.1097/00000658-199605000-00006 pubmed: 8651741 pmcid: 1235171
Wade TP, Virgo KS, Johnson FE (1995) Distal pancreatectomy for cancer: results in US Department of Veterans Affairs hospitals, 1987–1991. Pancreas 11(4):341–344
doi: 10.1097/00006676-199511000-00004 pubmed: 8532649
de Rooij T, Tol JA, van Eijck CH, Boerma D, BonsingBA BK, van Dam RM, Dijkgraaf MG, Gerhards MF, van Goor H, van der Harst E, de Hingh IH, Kazemier G, Klaase JM, Molenaar IQ, Patijn GA, van Santvoort HC, Scheepers JJ, van der Schelling GP, Sieders E et al (2016) Outcomes of distal pancreatectomy for pancreatic ductal adenocarcinoma in the Netherlands: a nationwide retrospective analysis. Ann Surg Oncol 23(2):585–591
doi: 10.1245/s10434-015-4930-4 pubmed: 26508153
Paye F, Micelli Lupinacci R, Bachellier P, Boher JM, Delpero JR, French Surgical A (2015) Distal pancreatectomy for pancreatic carcinoma in the era of multimodal treatment. Br J Surg 102(3):229–236
doi: 10.1002/bjs.9708 pubmed: 25533421
Ruess DA, Makowiec F, Chikhladze S, Sick O, Riediger H, Hopt UT, Wittel UA (2015) The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma. BMC Surg 15:123
doi: 10.1186/s12893-015-0110-5 pubmed: 26615588 pmcid: 4663036
Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D (2015) ESMO Guidelines Committee (2015) Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v56–v68
doi: 10.1093/annonc/mdv295 pubmed: 26314780
Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR et al (2019) Pancreatic adenocarcinoma, Version 1.2019. J Natl Compr Cancer Netw 17(3):202–210
doi: 10.6004/jnccn.2019.0014
Hartwig W, Vollmer CM, Fingerhut A, Yeo CJ, Neoptolemos JP, Adham M, Andren-Sandberg A, Asbun HJ, Bassi C, Bockhorn M, Charnley R, Conlon KC, Dervenis C, Fernandez-Cruz L, Friess H, Gouma DJ, Imrie CW, Lillemoe KD, Milicevic MN et al (2014) Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Surgery 156(1):1–14
doi: 10.1016/j.surg.2014.02.009 pubmed: 24856668
Stefanidis D, Grove KD, Schwesinger WH, Thomas CR Jr (2006) (2006) The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review. Ann Oncol 17(2):189–199
doi: 10.1093/annonc/mdj013 pubmed: 16236756
Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61:344–349
doi: 10.1016/j.jclinepi.2007.11.008
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP (2017) The eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67:93–99
doi: 10.3322/caac.21388 pubmed: 28094848
Navez J, Marique L, Hubert C, Van Laethem JL, Komuta M, Maris C, D'Haene N, Navez B, Closset J (2020) Distal pancreatectomy for pancreatic neoplasia: is splenectomy really necessary? A bicentric retrospective analysis of surgical specimens. HPB (Oxford) 22(11):1583–1589
doi: 10.1016/j.hpb.2020.01.016 pubmed: 32067888
Clavien P, Sanabria J, Strasberg S (1992) Proposed classification of complication of surgery with examples of utility in cholecystectomy. Surgery 111:518–526
pubmed: 1598671
Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, Neoptolemos J, Sarr M, Traverso W, Buchler M, International Study Group on Pancreatic Fistula Definition (2005) Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 138(1):8–13. https://doi.org/10.1016/j.surg.2005.05.001
doi: 10.1016/j.surg.2005.05.001 pubmed: 16003309
Leon P, Giannone F, Belfiori G, Falconi M, Crippa S, Boggi U, Menonna F, Al Sadairi AR, Piardi T, Sulpice L, Gardini A, Sega V, Chirica M, Ravazzoni F, Giannandrea G, Pessaux P, de Blasi V, Navarro F, Panaro F (2021) The oncologic impact of pancreatic fistula after distal pancreatectomy for pancreatic ductal adenocarcinoma of the body and the tail: a multicenter retrospective cohort analysis. Ann Surg Oncol 28(6):3171–3183. https://doi.org/10.1245/s10434-020-09310-y Epub 2020 Nov 6
doi: 10.1245/s10434-020-09310-y pubmed: 33156465
Bosman FT, Carneiro F, Hruban RH, Theise ND (2010) WHO classification of tumours of the digestive system. In: IARC (ed) WHO Classification of Tumours, vol 3, 4th edn
Campbell F, Cairns A, Duthie F, Feakins R. (2007) Dataset for the histopathological reporting of carcinomas of the pancreas, ampulla of Vater and common bile duct from the Royal College of Pathologists.
Tzeng CW, Fleming JB, Lee JE et al (2012) Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol 19(6):2045–2053
doi: 10.1245/s10434-011-2211-4 pubmed: 22258816
Poruk KE, Gay DZ, Brown K et al (2013) The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med 13(3):340–351
pubmed: 23331006 pmcid: 4419808
Isaji S, Mizuno S, Windsor JA et al (2018) International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 18(1):2–11
doi: 10.1016/j.pan.2017.11.011 pubmed: 29191513
The National Comprehensive Cancer Network (NCCN). Pancreatic adenocarcinoma 2019; Version 3.2019, 07/02/19. https://www.nccn.org/professio
Kim JK, DePeralta DK, Ogami T, Denbo JW, Pimiento J, Hodul PJ, Malafa MP, Kim DW, Fleming JB, Powers BD (2020) Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: a retrospective cohort analysis. J Surg Oncol 122(6):1074–1083
doi: 10.1002/jso.26103 pubmed: 32673436
Panzeri F, Marchegiani G, Malleo G, Malpaga A, Maggino L, Marchese T, Salvia R, Bassi C, Butturini G (2017) Distal pancreatectomy associated with multivisceral resection: results from a single centre experience. Langenbeck's Arch Surg 402(3):457–464
doi: 10.1007/s00423-016-1514-0
Grego A, Friziero A, Serafini S, Belluzzi A, Moletta L, Saadeh LM, Sperti C (2021) Does pancreatic fistula affect long-term survival after resection for pancreatic cancer? A systematic review and meta-analysis. Cancers (Basel) 13(22):5803
doi: 10.3390/cancers13225803 pubmed: 34830957
Sahakyan MA, Kleive D, Kazaryan AM, Aghayan DL, Ignjatovic D, Labori KJ, Røsok BI, Edwin B (2018) Extended laparoscopic distal pancreatectomy for adenocarcinoma in the body and tail of the pancreas: a single-center experience. Langenbeck's Arch Surg 403(8):941–948
doi: 10.1007/s00423-018-1730-x
Neoptolemos JP, Dunn JA, Stocken DD et al (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358:1576–1585
doi: 10.1016/S0140-6736(01)06651-X pubmed: 11716884
Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277
doi: 10.1001/jama.297.3.267 pubmed: 17227978
Assifi MM, Lu X, Eibl G et al (2011) Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 150:466–473
doi: 10.1016/j.surg.2011.07.006 pubmed: 21878232
Gillen S, Schuster T, Meyer Zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267
doi: 10.1371/journal.pmed.1000267 pubmed: 20422030 pmcid: 2857873
Denost Q, Laurent C, Adam JP et al (2013) Pancreaticoduodenectomy following chemoradiotherapy for locally advanced adenocarcinoma of the pancreatic head. HPB (Oxford) 15:716–723
doi: 10.1111/hpb.12039 pubmed: 23458326
Beetz O, Sarisin A, Kaltenborn A, Klempnauer J, Winkler M, Grannas G (2020) Multivisceral resection for adenocarcinoma of the pancreatic body and tail-a retrospective single-center analysis. World J Surg Oncol 18(1):218
doi: 10.1186/s12957-020-01973-x pubmed: 32819373 pmcid: 7441692

Auteurs

Cecilia Ferrari (C)

HPB and Transplant Unit, University of Montpellier, Montpellier, France. ferraricecilia.unige@gmail.com.
Ospedale Policlinico San Martino, Genova, Italy. ferraricecilia.unige@gmail.com.

Piera Leon (P)

HPB and Transplant Unit, University of Montpellier, Montpellier, France.

Massimo Falconi (M)

Chirurgia Pancreatica, IRCCS Ospedale San Raffaele, Milano, Italy.

Ugo Boggi (U)

Chirurgia HPB e Trapianto di Fegato, Ospedale Cisanello, Università degli Studi di Pisa, Pisa, Italy.

Tullio Piardi (T)

Reims University Hospital, Reims, France.

Laurent Sulpice (L)

Rennes University Hospital, Rennes, France.

Davide Cavaliere (D)

Ospedale di Forlì, Forlì, Italy.

Edoardo Rosso (E)

Department of Surgery, Istituto Fondazione Poliambulanza, Brescia, Italy.

Mircea Chirica (M)

Grenoble Alpes University Hospital, Grenoble, France.

Ferruccio Ravazzoni (F)

Ospedale di Alessandria, Alessandria, Italy.

Riccardo Memeo (R)

University of Bari, Bari, Italy.

Patrick Pessaux (P)

CHU Strasbourg University Hospital, Strasbourg, France.

Vito De Blasi (V)

Service de Chirurgie Générale et Mini-Invasive, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.

Matteo Mascherini (M)

Ospedale Policlinico San Martino, Genova, Italy.

Franco De Cian (F)

Ospedale Policlinico San Martino, Genova, Italy.

Francis Navarro (F)

HPB and Transplant Unit, University of Montpellier, Montpellier, France.

Fabrizio Panaro (F)

HPB and Transplant Unit, University of Montpellier, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH